No new adverse events reported for DTaP vaccination

(HealthDay)—No new or unexpected safety issues have been identified in association with diphtheria-tetanus-acellular pertussis (DTaP) vaccines in the United States, according to a study published online June 4 in Pediatrics. Pedro L. Moro, M.D., M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues searched the Vaccine Adverse Event Reporting System (VAERS) for U.S. reports of […]

Continue reading »

New study points to a potential ‘Achilles heel’ in brain cancer

Scientists at Virginia Commonwealth University believe they have uncovered an “Achilles heel” of glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. Their study published this week in the Proceedings of the National Academy of Sciences details how a mechanism that protects glioma stem cells can potentially be exploited to develop new and more effective treatments for […]

Continue reading »

13 DIY Father’s Day Gifts

It’s that time of June again: when we celebrate all the incredible dads, pops, grandpas, gramps and the like in our lives. But finding the perfect gift can feel tricky to say the least. For one thing, how did all the dads we know somehow end up that special mix of goofball and critic that make them really hard to shop […]

Continue reading »

Cervical cancer may be driven by imbalance in vaginal bacteria, research finds

Virtually all cervical cancers are caused by HPV, or human papillomavirus, dubbed the “common cold” of sexually transmitted infections because nearly every sexually active person catches it. Fortunately, the immune system vanquishes the majority of HPV infections, with only a small percentage progressing to precancer and, ultimately, cancer. But why do some people clear the infection while others are unable […]

Continue reading »

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node¬-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more […]

Continue reading »

Positive results for phase 1 trial of ivosidenib against AML

Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib show an overall response rate of 41.9 percent, with median progression free survival of 8.2 months. Twenty-four percent of patients achieved a complete response. The gene IDH1 […]

Continue reading »

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. The multi-center Phase I trial, led by researchers at The University of Texas MD Anderson Cancer Center, was designed to determine ivosidenib’s safety and […]

Continue reading »

Lipid molecules can be used for cancer growth

When the blood supply is low, cancer cells can use lipid molecules as fuel instead of blood glucose. This has been shown in animal tumour models by researchers at Karolinska Institutet, Sweden, in a study published in Cell Metabolism. The mechanism may explain why tumours often develop resistance to cancer drugs that inhibit the formation of blood vessels. Tumour growth […]

Continue reading »
1 331 332 333 334 335 388